No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly females |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D07
- Name in latin
- Carcinoma in situ endometrii (corporis uteri)
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of endometrium
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of endometrium
- Carcinoma in situ of other and unspecified genital organs
- Carcinoma in situ of other and unspecified genital organs
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 669 | 669 | - |
| Only index persons | 611 | 611 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | - |
| Only index persons | 0.02 | 0.02 | - |
| Median age at first event (years) | |||
| Whole population | - | 64.51 | - |
| Only index persons | - | 63.61 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 157 | 157 | - |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | - |
| Median age at first event (years) | 62.28 | 62.28 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 140
- Matched controls
- 1399
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D07.0
ICD-10 Finland
Carcinoma in situ: Endometrium
+∞
199.1
139
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
85.4
73
*
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
229.6
73.2
70
6
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
53.7
70.9
86
40
8380/3-C54.1
ICD-O-3
Endometrioid adenocarcinoma, NOS, of endometrium
+∞
59.7
53
*
PJA01
NOMESCO Finland
Laparoscopic sentinel node excision
+∞
56.1
50
*
N95.0
ICD-10 Finland
Postmenopausal bleeding
11.1
30.1
65
101
N85.1
ICD-10 Finland
Endometrial adenomatous hyperplasia
36.7
28.4
36
13
B01AB10
ATC
tinzaparin; parenteral
18.3
27.1
43
33
ZXC96
NOMESCO Finland
Robot assisted procedure
115.7
26.8
28
*
JN4BD
NOMESCO Finland
Extensive body CT
11.6
19.2
37
42
LCB25
NOMESCO Finland
Hysteroscopic excision of lesion
9.6
18.2
39
54
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
18.1
17
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
+∞
17.0
16
*
N84.0
ICD-10 Finland
Polyp of corpus uteri
6.5
16.8
49
107
8380/3-C54.9
ICD-O-3
Endometrioid adenocarcinoma, NOS, of corpus uteri
+∞
14.8
14
*
B01AB05
ATC
enoxaparin; parenteral
4.3
14.4
70
262
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
20.9
13.8
20
11
128
Kela drug reimbursment
Cancers of female genital organs
+∞
13.8
13
*
N85.0
ICD-10 Finland
Endometrial glandular hyperplasia
16.2
13.3
21
15
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
12.7
12
*
115
Kela drug reimbursment
Breast cancer
+∞
11.6
11
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
11.6
11
*
C54.10
ICD-10 Finland
Malignant tumor of endometrium without histology
+∞
10.5
10
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
10.5
10
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
10.5
10
*
H02AB02
ATC
dexamethasone; systemic
20.8
10.5
15
8
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
5.1
10.1
33
79
SPAT1312
SPAT
General health counselling
3.2
9.6
72
348
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
9.5
9
*
LCA06
NOMESCO Finland
Biopsy of endometrium
3.9
9.1
41
134
XX3DW
NOMESCO Finland
Time consuming IT work
7.5
9.1
21
32
ULC02
NOMESCO Finland
Hysteroscopy
6.1
8.8
24
46
L02BA01
ATC
tamoxifen; oral
+∞
8.4
8
*
WF090
NOMESCO Finland
Profylactic radiotherapy
+∞
8.4
8
*
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
+∞
8.4
8
*
SPAT1301
SPAT
No procedures
2.9
8.1
67
334
LCD11
NOMESCO Finland
Laparoscopically assisted vaginal hysterectomy
14.2
8.1
13
10
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
84.4
7.5
8
*
SAB01
NOMESCO Finland
Restricted oral and dental health check by dental hygienist or dental assistant
5.4
7.4
22
47
SPAT1249
SPAT
Treatment-related counselling outside office
2.7
7.4
79
457
PJD63
NOMESCO Finland
Laparoscopic dissection of aortic lymph nodes
+∞
7.3
7
*
LCA13
NOMESCO Finland
Curettage of cervix and body of uterus
4.2
7.1
27
75
TLC00
NOMESCO Finland
Insertion of intrauterine device
6.1
6.9
18
33
SPAT1153
SPAT
Removal of sutures
2.6
6.8
64
338
LCD04
NOMESCO Finland
Laparoscopic hysterectomy
5.9
6.7
18
34
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
4.0
6.6
26
75
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
6.3
6
*
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
7.8
6.1
13
18
SPAT1310
SPAT
Counselling related to known health issue
2.5
6.0
63
346
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
67
34
33.63
92.19
1.2
1.4
76.6
57.6
pmol/l
1.48
67
34
104
175
15.64
69.92
9.9
6.4
—
—
—
0
0
58
92
9.41
38.12
1.4
1.9
0.2
0.2
g/l
3.41
58
87
110
355
8.01
36.15
5.6
4.4
0.0
0.0
estimate
0.00
16
119
53
111
6.70
26.15
2.1
2.5
62.3
60.6
ml/min/173m2
0.12
26
42
39
61
8.18
25.25
3.2
4.9
95.0
94.3
%
0.81
39
61
43
80
7.03
23.67
5.7
8.0
24.6
26.1
mmol/l
1.86
43
75
113
528
5.07
20.24
5.9
4.3
—
—
—
0
0
116
584
4.78
18.03
4.5
3.5
—
—
—
0
0
46
128
4.67
15.82
3.2
5.2
5.2
5.5
kpa
0.73
46
123
46
128
4.67
15.82
3.2
5.2
13.3
12.0
kpa
0.87
46
123
124
700
4.67
15.41
5.8
4.1
0.0
0.0
estimate
0.50
16
117
106
541
3.95
15.16
3.4
3.3
37.1
35.8
g/l
2.13
98
497
46
132
4.51
15.16
3.1
5.0
1.3
2.1
mmol/l
1.19
34
110
122
691
4.43
14.84
5.9
4.1
0.0
0.0
estimate
0.00
16
120
121
694
4.24
14.14
6.4
5.7
0.0
0.0
estimate
0.00
13
115
44
130
4.31
13.86
3.5
3.7
104.2
103.5
mmol/l
0.47
44
125
61
297
2.72
8.11
1.4
1.4
—
—
—
0
0
76
443
2.39
6.63
3.0
3.1
—
—
—
0
0
19
52
4.02
6.42
1.5
1.4
—
—
—
0
0
76
501
2.00
4.36
4.8
3.6
18.5
105.5
ng/l
0.64
55
337
86
596
1.98
4.24
3.5
4.5
1.2
1.2
mmol/l
6.75
77
522
87
1105
0.52
3.80
10.2
15.2
14.3
13.7
%
2.50
82
1083
20
81
2.68
3.63
1.3
1.7
—
—
—
0
0
46
271
1.99
3.51
1.9
1.9
—
—
—
0
0
96
725
1.83
3.33
6.6
6.5
4.1
4.1
e9/l
0.05
89
628
22
422
0.44
3.21
1.5
1.6
1.6
1.3
mmol/l
0.40
17
356
97
749
1.77
2.98
4.0
3.8
6.8
6.6
mmol/l
0.42
92
688
86
645
1.74
2.90
3.8
5.0
1.2
1.2
mmol/l
6.62
74
557
131
1139
1.91
2.37
5.5
4.4
15.4
14.8
pmol/l
2.00
122
1040
146
1324
2.47
2.28
15.8
12.1
26.3
19.5
mg/l
1.04
123
1001
5
9
5.69
2.23
2.4
1.3
1644.3
8.2
u/ml
—
5
9
117
999
1.67
2.07
5.3
5.2
80.2
75.3
u/l
0.47
111
900
9
33
2.83
1.96
1.8
1.2
—
—
—
0
0
8
29
2.85
1.82
2.9
2.8
—
—
—
0
0
0
43
0.00
1.55
0.0
1.5
—
—
—
0
0
0
44
0.00
1.54
0.0
1.5
—
—
—
0
0
0
38
0.00
1.36
0.0
1.6
—
—
—
0
0
9
42
2.21
1.36
2.0
1.3
—
—
—
0
0
150
1429
2.11
1.28
18.0
13.9
71.2
70.5
umol/l
0.13
150
1429
58
460
1.41
1.24
2.9
2.0
2.4
2.4
mmol/l
0.74
52
370
20
302
0.61
1.23
1.3
1.2
0.7
1.4
u/ml
—
9
85
41
310
1.44
1.13
1.5
1.7
0.7
1.0
mg/l
0.90
31
241
24
162
1.57
1.12
1.4
1.6
26.8
29.4
s
2.05
24
154
139
1298
1.62
1.11
6.6
5.9
41.1
39.7
mmol/mol
1.01
130
1213
18
114
1.65
1.08
3.0
3.7
231.0
238.9
u/l
0.22
18
107
72
834
0.75
1.01
2.4
2.8
50.0
39.1
u/l
0.50
65
766
9
52
1.77
0.94
1.3
1.2
—
—
—
0
0
9
52
1.77
0.94
1.3
1.2
—
—
—
0
0
11
63
1.80
0.92
1.6
2.4
1.3
1.1
%
0.49
11
63
52
625
0.75
0.92
2.2
2.3
78.2
81.9
nmol/l
0.46
47
546
30
393
0.71
0.92
2.1
2.4
28.6
27.7
u/l
0.16
25
380
138
1301
1.50
0.87
4.6
4.3
1.4
1.3
mmol/l
1.06
125
1182
6
31
1.97
0.85
2.3
2.1
—
—
—
0
0
19
132
1.50
0.80
1.6
1.8
—
—
—
0
0
0
24
0.00
0.80
0.0
1.7
—
—
—
0
0
0
25
0.00
0.80
0.0
1.2
—
—
—
0
0
144
1375
1.57
0.78
5.4
4.8
6.2
5.9
mmol/l
2.70
136
1267
12
75
1.65
0.77
1.9
1.4
—
—
—
0
0
9
55
1.67
0.75
1.7
1.3
—
—
—
0
0
5
25
2.03
0.73
1.8
1.4
—
—
—
0
0
146
1402
1.59
0.72
5.7
5.4
2.9
2.8
mmol/l
0.25
134
1292
53
617
0.79
0.69
1.9
2.0
95.2
100.2
pmol/l
0.44
37
257
5
28
1.81
0.66
1.0
1.1
—
—
—
0
0
138
1317
1.40
0.64
6.4
5.4
2.7
1.9
mu/l
0.78
129
1205
11
71
1.59
0.64
1.5
1.4
—
—
—
0
0
68
763
0.81
0.62
2.4
2.8
—
—
—
0
0
7
114
0.60
0.60
3.9
2.9
—
—
—
0
0
0
21
0.00
0.60
0.0
1.5
—
—
—
0
0
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
13
94
1.42
0.47
1.8
3.2
1.2
1.3
mmol/l
0.40
13
89
37
315
1.23
0.46
2.1
2.1
326.1
10404.0
umol/l
2.54
31
268
142
1376
1.33
0.43
5.1
4.8
4.8
4.8
mmol/l
0.25
131
1272
5
32
1.58
0.42
1.2
1.4
—
—
—
0
0
17
132
1.32
0.42
1.3
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
2.2
—
14.1
—
0
6
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
6
88
0.67
0.34
1.2
1.7
—
—
—
0
0
7
97
0.71
0.32
1.6
1.5
—
—
—
0
0
38
341
1.15
0.27
2.3
2.3
4.9
3.2
mg/l
1.77
33
283
5
40
1.26
0.22
1.0
1.1
—
—
—
0
0
139
1362
1.18
0.21
4.9
4.7
1.5
1.6
mmol/l
1.63
127
1255
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
5.8
—
—
—
0
0
0
13
0.00
0.21
0.0
2.6
—
13.4
—
0
13
0
14
0.00
0.20
0.0
1.0
—
620.3
—
0
8
0
14
0.00
0.20
0.0
1.0
—
30.7
—
0
8
0
14
0.00
0.20
0.0
1.1
—
3.1
—
0
9
108
1045
1.11
0.20
4.5
4.5
15.6
12.9
mm/h
0.98
99
958
33
301
1.12
0.19
1.5
1.6
477.2
477.6
pmol/l
0.00
26
243
5
69
0.72
0.17
1.0
1.0
—
—
—
0
0
6
78
0.76
0.16
1.2
1.6
—
—
—
0
0
62
591
1.08
0.15
2.2
2.9
114.9
85.3
ug/l
0.77
57
547
31
286
1.10
0.15
1.2
1.3
12.3
15.5
u/ml
0.11
21
109
8
99
0.80
0.14
1.5
1.3
1.5
1.3
%
—
8
87
27
293
0.91
0.14
1.3
1.4
34.3
45.2
iu/ml
—
9
96
5
63
0.79
0.08
2.6
3.1
24.6
25.5
mmol/l
—
5
63
21
221
0.94
0.04
1.7
1.5
—
—
—
0
0
19
184
1.04
0.00
1.6
1.7
—
—
—
0
0
12
124
0.97
0.00
2.3
1.9
402.7
351.9
nmol/l
1.06
12
117
127
1272
0.99
0.00
7.9
11.1
75.9
76.4
ml/min/173m2
0.10
108
998
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
70.8
—
0
9
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
10.1
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_INSITU_ENDOMETRIUM_EXALLC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_INSITU_ENDOMETRIUM_EXALLC | 1.441 [1.14, 1.82] | 0.002 |
| Birth year | 0.995 [0.99, 1.0] | 0.296 |
During the follow-up period (1.1.1998 — 31.12.2019), 128 out of 537 females with CD2_INSITU_ENDOMETRIUM_EXALLC died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have CD2_INSITU_ENDOMETRIUM_EXALLC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.146% | No data |
| 5 | 0.753% | No data |
| 10 | 2.053% | No data |
| 15 | 3.884% | No data |
| 20 | 7.04% | No data |
Relationships between endpoints
↥Index endpoint: CD2_INSITU_ENDOMETRIUM_EXALLC – Carcinoma in situ of endometrium
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data